NICE Rejects Vidaza, But Celgene Plans Comparator-Based Appeal
Cancer drug is effective but still too expensive even with a 7 percent price cut, NICE concludes.
Cancer drug is effective but still too expensive even with a 7 percent price cut, NICE concludes.